Related Experiment Video
Updated: Jun 23, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
Published on: September 17, 2015
Origin and evaluation of depressed inotropism in hypertensive cardiomyopathy
J F Viallard1, S Bonoron-Adele, P Dos Santos
1INSERM Cardiologie, Bordeaux-Pessac, France.
Insights
Left ventricular hypertrophy (LVH) impairs heart contractility and relaxation, making it sensitive to ischemia. Treatments blocking the renin-angiotensin or sympathetic nervous systems effectively reverse LVH.
Area of Science:
- Cardiology
- Physiology
- Pathophysiology
Background:
- Left ventricular pressure overload induces left ventricular hypertrophy (LVH) as an adaptive response.
- LVH leads to impaired myocardial contractility and relaxation, increasing sensitivity to ischemia and hemodynamic changes.
- Coronary microvascular alterations contribute to increased vascular resistance in LVH.
Purpose of the Study:
- To investigate the functional and structural changes in the hypertrophied myocardium due to pressure overload.
- To explore the impact of LVH on systolic function and coronary hemodynamics.
- To evaluate the efficacy of different drug classes in reversing LVH.
Main Methods:
- Experimental studies using papillary muscles and isolated coronary-perfused hearts from renovascular hypertensive rats.
- Measurement of myocardial contractility, isometric timing, and left ventricular pressure.
- Analysis of coronary vascular resistance in human and animal models.
- Assessment of LVH regression with angiotensin-converting enzyme inhibitors, calcium-channel blockers, and beta-blockers.
Main Results:
- Papillary muscles showed decreased shortening velocity, increased isometric timing, and elevated developed pressure.
- Isolated hearts exhibited impaired systolic function under major loading conditions.
- Both human and animal studies indicated increased coronary vascular resistance.
- Only drugs targeting the renin-angiotensin system or sympathetic nervous system effectively reversed LVH.
Conclusions:
- LVH significantly impairs myocardial contractility and relaxation, with functional deficits becoming apparent under increased loading.
- Alterations in coronary microvasculature contribute to increased resistance in LVH.
- Pharmacological interventions targeting the renin-angiotensin and sympathetic nervous systems are most effective for LVH regression.
Abstract:
Left ventricular pressure overload results in the development of left ventricular hypertrophy (LVH) which is considered an adaptive mechanism of the heart to normalize systolic wall-stress. Impairment of both contractility and relaxation occurs, implying that the hypertrophied myocardium is very sensitive to ischaemia, alterations in coronary haemodynamics and to mechanisms incompletely understood. Experimental data from papillary muscles and isolated coronary perfused hearts (renovascular hypertensive rats) demonstrated respectively: a decrease in velocity of shortening, an increase in isometric timing parameters, and an increase in developed pressure. In contrast, the first derivative of left ventricular pressure, normalized to developed pressure, was decreased for large balloon volumes, suggesting an impairment of systolic function at major loading in LVH. In humans, left ventricular systolic dysfunction occurs later (congestive heart failure) when ejection fraction is impaired. Increases in total minimal vascular coronary resistances observed both in humans and in animals could be related to structural and functional alterations in coronary microvessels. Studies of LVH regression under treatment with angiotensin-converting enzyme inhibitors, calcium-channel blockers and beta-receptor blockers have confirmed that only drugs that block the renin-angiotensin system or the sympathetic nervous system are effective in maximizing the reversal of LVH.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management

